Effect of acute exacerbations on circulating endothelial, clotting and fibrinolytic markers in COPD patients

Internal and Emergency Medicine

Volumn 8, Issue 7, 2013, Pages 567-574

  Polosa, Riccardo ^a   Malerba, Mario ^b   Cacciola, Rossella R ^a   Morjaria, Jaymin B ^c   Maugeri, Cinzia ^a   Prosperini, Gaetano ^d   Gullo, Raimondo ^a   Spicuzza, Lucia ^a   Radaeli, Alessandro ^e   Di Maria, Giuseppe U ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^d CANNIZZARO HOSPITAL   (Italy)

^e Dipartimento di Emergenza   (Italy)

Author keywords

Clotting; COPD; D Dimer; Inflammation; Interleukin 6; Plasminogen activator inhibitor 1; von Willebrand's factor

Indexed keywords

BIOLOGICAL MARKER; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; INTERLEUKIN 6; PEPTIDE FRAGMENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; PROTHROMBIN FRAGMENT 1.2; VON WILLEBRAND FACTOR;

AGED; ARTICLE; BLOOD; BLOOD CLOTTING; BLOOD GAS ANALYSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; FEMALE; HUMAN; INFLAMMATION; MALE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SPIROMETRY; VASCULAR ENDOTHELIUM;

AGED; BIOLOGICAL MARKERS; BLOOD COAGULATION; BLOOD GAS ANALYSIS; ENDOTHELIUM, VASCULAR; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; PEPTIDE FRAGMENTS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPIROMETRY; VON WILLEBRAND FACTOR;

EID: 84884534967     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-011-0636-1     Document Type: Article

References (40)

1. Wedzicha JA, Donaldson GC (2003) Exacerbations of chronic obstructive pulmonary disease. Respir Care 48(12): 1204-1213 discussion 1213-1205.
2. Roland M, Bhowmik A, Sapsford RJ, Seemungal TA, Jeffries DJ, Warner TD, Wedzicha JA (2001) Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease. Thorax 56(1): 30-35.
3. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA (2000) Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 55(2): 114-120.
4. Montuschi P, Sala A, Dahlen SE, Folco G (2007) Pharmacological modulation of the leukotriene pathway in allergic airway disease. Drug Discov Today 12: 404-412.
5. Kerr R, Stirling D, Ludlam CA (2001) Interleukin 6 and haemostasis. Br J Haematol 115(1): 3-12.
6. Newby DE, Stewart A, Witherow FN, Grieve S, Dawson P, Fox KA, Webb DJ, Ludlam CA (2000) Local and systemic effects of intra-arterial desmopressin in healthy volunteers and patients with type 3 von Willebrand disease. Role of interleukin-6. Thromb Haemost 84(2): 195-203.
7. Cirino G, Napoli C, Bucci M, Cicala C (2000) Inflammation-coagulation network: are serine protease receptors the knot? Trends Pharmacol Sci 21(5): 170-172.
8. Esmon CT (2003) Inflammation and thrombosis. J Thromb Haemost 1(7): 1343-1348.
9. Dahlback B (2000) Blood coagulation. Lancet 355(9215): 1627-1632.
10. Salgado A, Boveda JL, Monasterio J, Segura RM, Mourelle M, Gomez-Jimenez J, Peracaula R (1994) Inflammatory mediators and their influence on haemostasis. Haemostasis 24(2): 132-138.
11. Ambrosetti M, Ageno W, Spanevello A, Salerno M, Pedretti RF (2003) Prevalence and prevention of venous thromboembolism in patients with acute exacerbations of COPD. Thromb Res 112(4): 203-207.
12. Hartmann IJ, Hagen PJ, Melissant CF, Postmus PE, Prins MH (2000) Diagnosing acute pulmonary embolism: effect of chronic obstructive pulmonary disease on the performance of D-dimer testing, ventilation/perfusion scintigraphy, spiral computed tomographic angiography, and conventional angiography. ANTELOPE Study Group. Advances in New Technologies Evaluating the Localization of Pulmonary Embolism. Am J Respir Crit Care Med 162(6): 2232-2237.
13. Tillie-Leblond I, Marquette CH, Perez T, Scherpereel A, Zanetti C, Tonnel AB, Remy-Jardin M (2006) Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. Ann Intern Med 144(6): 390-396.
14. Rutschmann OT, Cornuz J, Poletti PA, Bridevaux PO, Hugli OW, Qanadli SD, Perrier A (2007) Should pulmonary embolism be suspected in exacerbation of chronic obstructive pulmonary disease? Thorax 62(2): 121-125.
15. Wedzicha JA, Hurst JR (2007) Chronic obstructive pulmonary disease exacerbation and risk of pulmonary embolism. Thorax 62(2): 103-104.
16. Polosa R, Cacciola RR, Prosperini G, Spicuzza L, Morjaria JB, Di Maria GU (2008) Endothelial-coagulative activation during chronic obstructive pulmonary disease exacerbations. Haematologica 93(8): 1275-1276.
17. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS (2001) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 163(5): 1256-1276.
18. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA (1987) Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 106(2): 196-204.
19. Montuschi P (2006) Pharmacological treatment of chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 1: 409-423.
20. Wedzicha JA, Syndercombe-Court D, Tan KC (1991) Increased platelet aggregate formation in patients with chronic airflow obstruction and hypoxaemia. Thorax 46(7): 504-507.
21. Alessandri C, Basili S, Violi F, Ferroni P, Gazzaniga PP, Cordova C (1994) Hypercoagulability state in patients with chronic obstructive pulmonary disease. Chronic Obstructive Bronchitis and Haemostasis Group. Thromb Haemost 72(3): 343-346.
22. Wedzicha JA, Seemungal TA, MacCallum PK, Paul EA, Donaldson GC, Bhowmik A, Jeffries DJ, Meade TW (2000) Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 84(2): 210-215.
23. Blann AD, McCollum CN, Lip GY (2002) Relationship between plasma markers of endothelial cell integrity and the Framingham cardiovascular disease risk-factor scores in apparently healthy individuals. Blood Coagul Fibrinolysis 13(6): 513-518.
24. Caponnetto P, Russo C, Di Maria A, et al. (2010) Circulating endothelial-coagulative activation markers after smoking cessation: a 12-month observational study. Eur J Clin Invest Dec 29. [Epub ahead of print].
25. Yan SF, Lu J, Zou YS, Soh-Won J, Cohen DM, Buttrick PM, Cooper DR, Steinberg SF, Mackman N, Pinsky DJ et al (1999) Hypoxia-associated induction of early growth response-1 gene expression. J Biol Chem 274(21): 15030-15040.
26. Gertler JP, Weibe DA, Ocasio VH, Abbott WM (1991) Hypoxia induces procoagulant activity in cultured human venous endothelium. J Vasc Surg 13(3): 428-433.
27. Ogawa S, Shreeniwas R, Brett J, Clauss M, Furie M, Stern DM (1990) The effect of hypoxia on capillary endothelial cell function: modulation of barrier and coagulant function. Br J Haematol 75(4): 517-524.
28. Le Roux G, Larmignat P, Marchal M, Richalet JP (1992) Haemostasis at high altitude. Int J Sports Med 13(Suppl 1): S49-S51.
29. Grover RF, Bartsch P (2002) High altitude: an exploration of human adaptation. Marcel Dekker, New York.
30. Kunter E, Ilvan A, Ozmen N, Demirer E, Ozturk A, Avsar K, Sayan O, Kartaloglu Z (2008) Effect of corticosteroids on hemostasis and pulmonary arterial pressure during chronic obstructive pulmonary disease exacerbation. Respiration 75(2): 145-154.
31. Cella G, Sbarai A, Mazzaro G, Vanzo B, Romano S, Hoppensteadt T, Fareed J (2001) Plasma markers of endothelial dysfunction in chronic obstructive pulmonary disease. Clin Appl Thromb Hemost 7(3): 205-208.
32. Yokoyama S, Ikeda H, Haramaki N, Yasukawa H, Murohara T, Imaizumi T (2005) Platelet P-selectin plays an important role in arterial thrombogenesis by forming large stable platelet-leukocyte aggregates. J Am Coll Cardiol 45(8): 1280-1286.
33. Sin DD, Lacy P, York E, Man SF (2004) Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170(7): 760-765.
34. Davies L, Angus RM, Calverley PM (1999) Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 354(9177): 456-460.
35. Lowe GD, Yarnell JW, Sweetnam PM, Rumley A, Thomas HF, Elwood PC (1998) Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study. Thromb Haemost 79(1): 129-133.
36. Rumley A, Lowe GD, Sweetnam PM, Yarnell JW, Ford RP (1999) Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study. Br J Haematol 105(1): 110-116.
37. Groenewegen KH, Schols AM, Wouters EF (2003) Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 124(2): 459-467.
38. Erelel M, Cuhadaroglu C, Ece T, Arseven O (2002) The frequency of deep venous thrombosis and pulmonary embolus in acute exacerbation of chronic obstructive pulmonary disease. Respir Med 96(7): 515-518.
39. Mispelaere D, Glerant JC, Audebert M, Remond A, Sevestre-Pietri MA, Jounieaux V (2002) [Pulmonary embolism and sibilant types of chronic obstructive pulmonary disease decompensations]. Rev Mal Respir 19(4): 415-423.
40. Willaert W, Daenen M, Bomans P, Verleden G, Decramer M (2002) What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations? Eur Respir J 19(5): 928-935.